August 8th 2024
Vijayakrishna Gadi, MD, PhD, discusses short-term and long-term treatments with ADCs.
Vijayakrishna Gadi, MD, PhD, discusses the risk of ILD and pneumonitis from ADCs.
August 1st 2024
Vijayakrishna Gadi, MD, PhD, discusses the role of antibody-drug conjugates in a curative setting.
A panel of experts discuss the challenges of testing for HER2-low access solid tumor types.
July 23rd 2024
A panel of experts discuss if there is a role for HER2-directed ADCs antibody-drug conjugates in GU genitourinary cancers
A panel of experts discuss where HER2-directed ADCs antibody-drug conjugates fit into the overall treatment paradigm.
July 12th 2024
Dr Garon shares insights on the role of ADCs for the treatment of HER2+ lung cancer.
Dr Gadi leads a discussion on recent data on the treatment of HER2-low tumors, including ASCO updates on the DESTINY-Breast06 trial.
Dr Parikh discusses the history of ADCs for treating GI cancers with a focus on the data for T-DXd and its role in treating these cancers.
Dr Campos discusses the potential for T-DXd in other gynecologic cancers and offers an overview of results from the DESTINY-PanTumor02 trial.
June 25th 2024
Dr Gadi introduces treatment and trial data targeting care for patients diagnosed with HER2+ breast cancer.
Dr Gadi leads a discussion surrounding HER2 mutation and overexpression across various cancer types.
March 25th 2024
Vijayakrishna Gadi, MD, PhD, and Megan Kruse, MD, discuss the clinical benefits reported with neratinib for the treatment of patients with HER2-positive early breast cancer.
Vijayakrishna Gadi, MD, PhD, and Megan Kruse, MD, discuss ongoing research efforts in HER2-positive early breast cancer.
March 18th 2024
Vijayakrishna Gadi, MD, PhD, and Megan Kruse, MD, discuss optimal management for adverse effects related to neratinib for patients with HER2-positive early breast cancer.
Vijayakrishna Gadi, MD, PhD, and Megan Kruse, MD, discuss unmet needs in the treatment of patients with HER2-positive early breast cancer.
March 12th 2024
Vijayakrishna Gadi, MD, PhD, and Megan Kruse, MD, discuss how standard-of-care treatment has evolved for patients with HER2-positive early breast cancer.
Vijayakrishna Gadi, MD, PhD, and Megan Kruse, MD, discuss clinical updates to the management of patients with HER2-positive early breast cancer.
August 24th 2021
Closing thoughts from a discussion regarding the treatment landscape for HER2-positive breast cancer, with insight supporting the role of novel therapies to help personalize therapy.
An overview of therapies under study in later-stage clinical trials to treat HER2-positive metastatic breast cancer.